The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis.
The gender, age, ICU diagnosis, basic diseases, antibiotic treatment plan, physiological indicators, duration of hospital stay, length of stay in ICU, hospitalization cost, prognosis and other discharge information of patients receiving tigecycline or polymyxin B admitted to the ICU of four provincial-level Grade A hospitals in Changsha, Hunan Province ,China from 2017 to 2021 were included. The four hospitals included the 1st-3th XiangYa Hospitals and Hunan Provincial People's Hospital. Organize the data.Patients with a course of treatment \< 4 days and shedding were excluded.To analyze the therapeutic effect of tigecycline-based or polymyxin B-based antibiotic regimens and their effect on the prognosis of patients, and to conduct subgroup analysis. The chi-square test was used for the counting data, and the Mann-Whitney U test or Kruskal-Wallis H test was used for the measurement data. The significance value was adjusted by Bonferroni correction method for multiple tests, and the P was tested on both sides,P\>0.05.
Study Type
OBSERVATIONAL
Enrollment
800
Xiangya Hospital of Central south university
Changsha, Hunan, China
RECRUITINGhospital mortality rate
Patients die in hospital or abandon treatment due to poor prognosis in hospital after treatment of tigecycline or polymyxin B
Time frame: up to hospital discharge or die in hospital, up to 48 weeks(estimation).
30d mortality rate
Patients die after treatment of tigecycline or polymyxin B
Time frame: up to the 30th day of the treatment of tigecycline or polymyxin B
Bacterial clearance rate
Bacterial clearance during treatment of tigecycline or polymyxin B
Time frame: from the first day of the treatment of tigecycline or polymyxin B until to the end day, up to 8 weeks (estimation).
The length of hospital stay
The length of hospital stay,days
Time frame: up to hospital discharge or die in hospital, up to 48 weeks (estimation).
The length of ICU stay
The length of ICU stay
Time frame: up to hospital discharge or die in hospital, up to 24 weeks (estimation).
Hospitalization Cost
total Hospitalization Cost
Time frame: up to hospital discharge or die in hospital, up to 48 weeks (estimation).
serum creatinine
serum creatinine at the end day of the treatment of tigecycline or polymyxin B
Time frame: at the end day of the treatment of tigecycline or polymyxin B, up to 8 weeks (estimation).
MV days
the total days with mechanical ventilation
Time frame: up to hospital discharge or die in hospital, up to 48 weeks (estimation).
VA days
the total days with vasoactive agent
Time frame: up to hospital discharge or die in hospital, up to 48 weeks (estimation).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.